Download MendeleySuper broad and protective nanobodies against Sarbecoviruses including SARS-CoV-1 and the divergent SARS-CoV-2 subvariant KP.3.1.1.
Dong, H., Zhou, R., Chen, J., Wei, J., Wei, Z., Yang, Z., Zhu, K., Yang, Y., Yang, Q., Liu, N., Chen, Y., Wu, Y., Liang, Y., Zeng, Y., Guo, Q., Li, M., Shan, S., Wang, H., Niu, M., Yunfei Zeng, I., Shi, X., Zhang, Q., Wang, X., Chen, Z., Zhang, L.(2024) PLoS Pathog 20: e1012625-e1012625
- PubMed: 39527594 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1371/journal.ppat.1012625
- Primary Citation Related Structures:
8Z2E - PubMed Abstract:
The ongoing evolution and immune escape of SARS-CoV-2, alongside the potential threat of SARS-CoV-1 and other sarbecoviruses, underscore the urgent need for effective strategies against their infection and transmission. This study highlights the discovery of nanobodies from immunized alpacas, which demonstrate exceptionally broad and potent neutralizing capabilities against the recently emerged and more divergent SARS-CoV-2 Omicron subvariants including JD.1.1, JN.1, KP.3, KP.3.1.1, as well as SARS-CoV-1 and coronaviruses from bats and pangolins utilizing receptor ACE2. Among these, Tnb04-1 emerges as the most broad and potent, binding to a conserved hydrophobic pocket in the spike's receptor-binding domain, distinct from the ACE2 binding site. This interaction disrupts the formation of a proteinase K-resistant core, crucial for viral-cell fusion. Notably, intranasal administration of Tnb04-1 in Syrian hamsters effectively prevented respiratory infection and transmission of the authentic Omicron XBB.1.5 subvariant. Thus, Thb04-1 holds promise in combating respiratory acquisition and transmission of diverse sarbecoviruses.
- Comprehensive AIDS Research Center, Pandemic Research Alliance Unit, Center for Infection Biology, School of Basic Medical Sciences, Tsinghua Medicine, Tsinghua University, Beijing, China.
Organizational Affiliation:
